Rhodium(III) Acetylacetonate [Rh(acac)₃] Customization Case: Halides (Cl⁻/Br⁻) <5ppm & Heavy Metal Impurities <1ppm

HiSiaddi is an innovative foreign trade service provider driven by dual engines of technology transformation and foreign trade services. It has established a service system summarized as "1+2+3+4=1" and can supply rhodium(III) acetylacetonate sourced from multiple well-known original manufacturers. As a foreign trader with independent R&D capabilities, HiSiaddi has repeatedly resolved customized product demands for rhodium(III) acetylacetonate through technological transformation cooperation with manufacturers and precise market demand insight. Below is a case of customized rhodium(III) acetylacetonate developed by HiSiaddi.

Please contact HiSiaddi customer service for more customized service inquiries.

I. Client Background

The client is PHARMAVANT GmbH, a high-end pharmaceutical CDMO headquartered in Zurich, Switzerland. It specializes in the R&D and production of key intermediates for anti-cancer drugs, premium antibiotics and biopharmaceuticals, serving the world’s top 20 pharmaceutical enterprises. The company complies with ICH Q7, EU GMP and Swiss Pharmacopoeia (Ph.Helv) standards, representing a high-end overseas client with high technical barriers and extremely stringent quality requirements.

Core Client Demand: Custom ultra-high-purity electronic-grade rhodium(III) acetylacetonate [Rh(acac)₃] as a homogeneous catalyst precursor for anti-cancer drug synthesis. Required specifications: purity ≥99.95%, halides (Cl⁻/Br⁻) <5ppm, heavy metal impurities <1ppm, particle size D50=3–5μm, inter-batch catalytic activity deviation <2%, sterile and pyrogen-free, compliant with pharmaceutical contact standards.

Previously, the client long relied on imports from Europe (Johnson Matthey), which came with high unit prices and long lead times (4–6 weeks). This was their first attempt to source from China. They contacted 3 domestic manufacturers, yet all failed to simultaneously meet four core customized indicators: ultra-high purity, ultra-low halide content, narrow particle size distribution and pharmaceutical-grade sterility. The client therefore entrusted HiSiaddi with full responsibility for customized development and mass production implementation.

II. Core Customization Pain Points: Four Severe Technical Bottlenecks

1.

Difficult control of ultra-high purity and ultra-low halide residues Halide residues cause side reactions and catalyst poisoning in pharmaceutical synthesis. Conventional processes adopt rhodium trichloride as raw material; Cl⁻ readily forms strong coordination bonds with Rh³⁺ to generate hard-to-remove byproducts [RhClₓ(acac)ᵧ]ⁿ⁻, making it challenging to stabilize halide levels below 5ppm. Meanwhile, purity must be upgraded from industrial grade 99.0% to 99.95%+, which leads to high purification loss and elevated costs.

2.

3.

Difficult customization of narrow particle size distribution (D50=3–5μm) The client’s catalyst requires high specific surface area and rapid dissolution in organic solvents. Conventional products feature particle sizes of 10–20μm with broad distribution, failing to meet requirements for instantaneous catalysis and high selectivity in pharmaceutical synthesis. Direct crushing introduces impurities and damages crystal structures, impairing catalytic activity.

4.

5.

Challenging pharmaceutical-grade sterile and pyrogen-free treatment Post high-purity synthesis, additional sterile filtration, vacuum low-temperature drying and sterile packaging procedures are required to eliminate microbial and pyrogen contamination. Most domestic precious metal manufacturers only hold industrial-grade production qualifications and lack clean workshops and sterile processing capabilities for pharmaceutical-grade production.

6.

7.

Hard to stabilize batch consistency and catalytic activity Anti-cancer drug synthesis tolerates minimal fluctuation in catalyst activity; deviations exceeding 2% reduce drug yield and raise impurity levels. Strict control of reaction temperature, pH, ligand concentration and crystallization rate is mandatory, while conventional domestic processes commonly suffer batch fluctuations over 5%, failing to meet specifications.

8.

III. HiSiaddi Customized Solution: Four Technical Breakthroughs & Full-Link Customization

HiSiaddi assembled a technical team consisting of precious metal synthesis engineers, pharmaceutical purification specialists, crystal morphology control technicians and sterile process engineers. We collaborated with Guiyan Chemical, a leading domestic precious metal enterprise with pharmaceutical-grade production qualifications that participates in drafting industry standards. Full-link customized development covering raw materials, synthesis processes, purification and post-treatment was completed within 45 days (lab test → pilot test → mass production), and the product passed all full-item testing at the client’s Swiss laboratory in one go.

1.

Raw Material Upgrade: Halogen-free rhodium source to control halides from the source Abandon traditional rhodium trichloride (RhCl₃) feedstock; adopt high-purity halogen-free rhodium nitrate [Rh(NO₃)₃, purity 99.99%, Cl⁻ <1ppm] as rhodium precursor to eliminate Cl⁻ introduction. Meanwhile, upgrade acetylacetonate ligand purity to ≥99.9% to reduce organic impurities and minimize byproduct formation risks at the source.

2.

3.

Process Restructuring: Low-temperature coordination + precise pH regulation to boost purity and activity Adopt CO₂ acidified alcohol-water mixed system to replace traditional strong alkaline environments. Mild pH neutralization suppresses competitive coordination of acid radicals and reduces formation of [RhClₓ(acac)ᵧ]ⁿ⁻ byproducts, stabilizing product purity above 99.95% and halide content below 3ppm. Precisely control reaction temperature at 65±2℃, stirring speed at 300rpm and ligand/rhodium molar ratio at 2.1:1 to ensure uniform crystal growth and lay a foundation for subsequent narrow particle size regulation.

4.

5.

Crystal & Particle Size Customization: Gradient cooling crystallization + low-temperature grinding to achieve D50=3–5μm

6.

· Gradient cooling crystallization: After reaction completion, cool down slowly at a rate of 1℃/h to 25℃ to generate fine, uniform single crystals and avoid large crystal agglomeration.

· Sterile low-temperature grinding: Conduct agate ball milling under nitrogen protection at ≤20℃ inside Class 100 clean workshops. Precisely control particle size D50 at 3.8μm (±0.5μm fluctuation), increasing specific surface area by 40% and guaranteeing rapid dissolution in organic solvents.

1. Pharmaceutical-Grade Post-Treatment: Aseptic Purification & Pyrogen-Free Packaging Compliant with GMP Standards

· Three-stage sterile filtration: Pass crystalline products sequentially through 0.45μm, 0.22μm and 0.1μm sterile filter membranes to remove microorganisms and particulate matter.

· Vacuum low-temperature drying: Dry under vacuum at 45℃ for 24 hours to fully remove moisture and residual solvents, with moisture content controlled below 0.1%.

· Sterile pyrogen-free packaging: Seal products inside Class A clean areas using medical-grade aluminum foil bags and light-proof explosion-proof cartons, with attached sterile test reports and pyrogen test reports to comply with EU pharmaceutical contact standards.

1. Batch Stability Control: Solidified full-process parameters + dual testing mechanism Fix 12 key process parameters including raw material ratio, reaction temperature, crystallization rate and grinding parameters, and establish a batch file traceability system. Each batch undergoes dual testing: internal self-inspection (ICP-MS, particle size analyzer, sterility test) and third-party SGS testing, ensuring full compliance of purity, impurities, particle size and activity with requirements, with inter-batch catalytic activity deviation controlled below 1.5%.

IV. Implementation Outcomes: Mass Production in 45 Days, Exceeded Target Specifications & Long-Term Exclusive Cooperation

1. 100% compliance with customized indicators, partial metrics exceeding requirements

· Purity: 99.97% (surpassing the client’s 99.95% requirement)

· Halides: 2.8ppm (below the 5ppm threshold)

· Heavy metal impurities: <0.8ppm

· Particle size: D50=3.8μm (within the 3–5μm target range)

· Catalytic activity deviation: 1.2% (below the 2% threshold)

· Sterility & pyrogen-free: Passed inspection, fully compliant with EU GMP standards

1. Optimized Cost & Lead Time with Significantly Improved Competitiveness

· Unit price: 35% lower compared with European imports

· Lead time: Reduced from 4–6 weeks to 2 weeks for mass production; lab samples delivered within 45 days

· Minimum order quantity: Support small-batch customization starting from 100g, matching client R&D and pilot production demands

1. Full Client Recognition & Locked Long-Term Exclusive Cooperation The client’s Swiss laboratory test report commented: “The product’s purity, impurity control, particle size uniformity and consistency of catalytic activity match the level of European supplier Johnson Matthey, with some indicators superior. HiSiaddi is the only Chinese partner capable of meeting customized demands for pharmaceutical-grade ultra-high-purity rhodium(III) acetylacetonate.”

The client terminated its long-term European supply partnership and awarded HiSiaddi exclusive rights to its full-year 5kg order of high-purity rhodium(III) acetylacetonate. The client also appointed HiSiaddi as its sole supplier for customized precious metal catalysts in China, and launched parallel customized development projects for pharmaceutical-grade rhodium octanoate, rhodium iodide and other products.

V. Case Summary

High-end overseas pharmaceutical CDMOs impose stringent customized requirements of ultra-high purity, ultra-low halide content, narrow particle size distribution and pharmaceutical-grade sterility on rhodium(III) acetylacetonate, which constitute technical barriers unbreakable by conventional domestic industrial-grade production. Core pain points converge in five dimensions: halide control from raw materials, purification technology, particle size regulation, sterile treatment and batch stability.

Relying on customized technical solutions, top-tier cooperative factory resources and full-process quality control capabilities, HiSiaddi broke cross-border technical and qualification barriers to realize customized mass production of pharmaceutical-grade ultra-high-purity rhodium(III) acetylacetonate. This solution helped the client cut procurement costs, shorten lead times and guarantee pharmaceutical synthesis quality, while enabling domestic manufacturers of high-end precious metal compounds to break through barriers in pharmaceutical-grade applications and enter the supply chains of top European pharmaceutical enterprises.

Please contact HiSiaddi customer service for more customized service inquiries.